1 / 3

Oral Drugs Molnupiravir(EIDD-2801) For Treat COVID 2019-APICDMO

APICDMO is the best Molnupiravir(EIDD-2801) ram materials manufacturer in China and support bulk order. Molnupiravir has the potential for COVID-19, seasonal and pandemic influenza treatment.Welcome to contact with us for more details!<br><br>https://www.apicdmo.com/product/2349386-89-4/

apicdmo
Download Presentation

Oral Drugs Molnupiravir(EIDD-2801) For Treat COVID 2019-APICDMO

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Oral Drugs Molnupiravir(EIDD-2801) For Treat COVID 2019-APICDMO Source From: www.apicdmo.com Time: 19th, Jan. 2022 www.apicdmo.com JINAN APICDMO BIOTECHNOLOGY CO., LIMITED Tel: +8613682461609 Email: emily@apicdmo.com

  2. Molnupiravir(EIDD-2801) Description CAS: 2349386-89-4 Molnupiravir(EIDD-2801) is an orally bioavailable prodrug of the antiviral nucleoside derivative N4- hydroxycytidine (NHC, EIDD-1931). It is a nucleotide analog inhibitor of RNA-dependent RNA polymerases (RdRps). The compound interferes with the action of viral RNA polymerase.Molnupiravir exerts its antiviral action through introduction of copying errors during viral RNA replication. The active drug incorporates into the genome of RNA viruses, leading to an accumulation of mutations known as viral error catastrophe. The broadspectrum antiviral agent EIDD-2801 inhibits viral RNA replication in various unrelated RNA viruses including influenza, Ebola, Venezuelan equine encephalitis virus (VEEV) and coronaviruses, including SARS-CoV, MERS-CoV and SARS-CoV-2. EIDD-2801 has the potential for COVID-19, seasonal and pandemic influenza treatment. Product CAS No. Synonyms Molnupiravir(EIDD-2801) 2349386-89-4 MK4482; EIDD-2801; Prodrug-EIDD-1931; Uridine, 4-oxime, 5'-(2-methylpropanoate). O[C@@H]([C@H]([C@H](N1C(N/C(C=C1)=N/O)=O)O2)O)[C@H]2 COC(C(C)C)=O InChI=1S/C13H19N3O7/c1-6(2)12(19)22-5-7-9(17)10(18)11(23-7)1 6-4-3-8(15-21)14-13(16)20/h3-4,6-7,9-11,17-18,21H,5H2,1-2H3,(H, 14,15,20)/t7-,9-,10-,11-/m1/s1 HTNPEHXGEKVIHG-QCNRFFRDSA-N In Stock C13H19N3O7 N/A Boiling Point White powder Purity Storage SMILES InChI InChI key Availability MF. Melting Point Appearance Application MW. 329.31 N/A 98% 0°C -20°C desiccated Download (short (long term), term), For research use only COA & NMR Download MSDS www.apicdmo.com JINAN APICDMO BIOTECHNOLOGY CO., LIMITED Tel: +8613682461609 Email: emily@apicdmo.com

  3. 【 【Reference】 】 [1] Nguyen KH, Nguyen K, Corlin L, Allen JD, Chung M. Changes in COVID-19 vaccination receipt and intention to vaccinate by socioeconomic characteristics and geographic area, United States, January 6 — March 29, 2021. Ann Med 2021;53:1419-1428. [2] Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med 2021;385:1941-1950. [3] Sheahan TP, Sims AC, Zhou S, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med 2020;12(541):eabb5883-eabb5883. [4] Urakova N, Kuznetsova V, Crossman DK, et al. β-d-N4-hydroxycytidine is a potent anti-alphavirus compound that induces a high level of mutations in the viral genome. J Virol 2018;92(3):e01965-e17. [5] Cowman K, Guo Y, Pirofski LA, et al. Post-severe acute respiratory syndrome coronavirus 2 monoclonal antibody treatment hospitalizations as a sentinel for emergence of viral variants in New York City. Open Forum Infect Dis 2021;8(8):ofab313-ofab313. www.apicdmo.com JINAN APICDMO BIOTECHNOLOGY CO., LIMITED Tel: +8613682461609 Email: emily@apicdmo.com

More Related